Orserdu Approved for ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer By Brian Park, PharmD Publish Date January 30, 2023
Updated Booster Shots, Not Original COVID-19 Vaccines, Should Be Standard: FDA Panel Publish Date January 30, 2023
Jaypirca Approved for Relapsed/Refractory Mantle Cell Lymphoma By Diana Ernst, RPh Publish Date January 27, 2023
FDA Approval Updates Enjaymo Indication for Cold Agglutinin Disease By Diana Ernst, RPh Publish Date January 27, 2023
Keytruda Approved as Adjuvant Treatment for Stage IB, II, or IIIA NSCLC By Diana Ernst, RPh Publish Date January 27, 2023
FDA Revises Evusheld EUA Halting Use of the COVID-19 Therapy for Now By Diana Ernst, RPh Publish Date January 26, 2023
Abbott’s SCS System Cleared for Patients With Painful Diabetic Peripheral Neuropathy By Diana Ernst, RPh Publish Date January 26, 2023
Trial Evaluating Lisocabtagene Maraleucel for Relapsed/Refractory CLL Meets Endpoint By Diana Ernst, RPh Publish Date January 26, 2023
Briumvi Now Available for Multiple Sclerosis Treatment By Diana Ernst, RPh Publish Date January 26, 2023
High-Dose Exercise No Better Than Low-Dose Exercise for Knee Osteoarthritis Publish Date January 26, 2023
Trial Investigating Pembrolizumab for Hormone-Sensitive Prostate Cancer Discontinued By Diana Ernst, RPh Publish Date January 25, 2023
FDA Panel Votes on Rezafungin for Treatment of Candidemia, Invasive Candidiasis By Diana Ernst, RPh Publish Date January 25, 2023
AKI, CKD Progression Less Likely With Direct Oral Anticoagulants By Jody A. Charnow Publish Date January 25, 2023
